Table II. Treatment outcomes.
| Overall Population (n = 112) | Anakinra + SOCa (n = 56) | SOC (n = 56) | p Valueb | |
|---|---|---|---|---|
| 28-d survival | 69 (61.6) | 42 (75.0) | 27 (48.2) | 0.007 |
| 28-d survival in orotracheal-intubated patients | 18/24 (75.0) | 11/14 (78.6) | 7/10 (70) | 0.634 |
| 28-d survival in CPAP-treated patients | 51/88 (58.0) | 31/42 (73.8) | 20/46 (43.5) | 0.008 |
| Major infective events | 24 (21.4) | 15 (26.8) | 9 (16.1) | 0.250 |
| 90-d survival | 63 (56.3) | 37 (66.1) | 26 (46.4) | 0.036 |
| 90-d ventilation-free survival | 41/88 (46.6) | 24/42 (58.5) | 17/46 (41.5) | 0.093 |
| Need of invasive ventilation | 17/88 (19.3) | 9/42 (21.4) | 8/46 (17.4) | 0.835 |
| Duration of recovery in survivors, days | 34 (18–48) | 35 (18–49) | 34 (18–48) | 0.950 |
Data are median value (interquartile range) or n (%), respectively, for continuous and categorical variables.
a
SOC included lopinavir/ritonavir (400/100 mg twice), hydroxychloroquine (200 mg twice by mouth), first-line antibiotic therapy (i.e., 500 mg of azithromycin daily by mouth and 2 g of ceftriaxone daily i.v.), and enoxaparin (4000 IU daily as standard but dosage adjusted based on thrombotic risk and d-dimer levels).
b
Mann–Whitney nonparametric test and Pearson χ2 test were used, respectively, to compare continuous and categorical variables of patients in the two groups.